ICPIs prevents tumor escape through the PD1/PD-L1 axis which is commonly utilized by cancers with a high mutational burden, as these malignancies express high levels of neoantigens that stimulate a cytotoxic immune response (7, 61) We observed an improved ICPI efficacy in lung, head and neck and gastro-esophageal junction cancers which all have a relatively high mutational burden (62). The gene discussed is CD274; the disease is neoplasm.